Quantcast

Latest Amgen Stories

2014-05-20 16:26:40

Early Data Demonstrate Anti-TSLP Therapy Reduces Early and Late Asthmatic Responses and Several Key Inflammatory Markers THOUSAND OAKS, Calif., May 20, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that The New England Journal of Medicine (NEJM) published positive results from a Phase 1 study adding to the growing body of evidence that inhibiting thymic stromal lymphopoietin (TSLP) could be beneficial in the treatment of asthma. TSLP is a cytokine thought to be a key...

2014-05-15 16:28:53

THOUSAND OAKS, Calif., May 15, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced voting results from the Company's Annual Meeting of Stockholders, held in Westlake Village, Calif. Approximately 88 percent of outstanding shares were represented at the meeting. The director nominees David Baltimore, Frank J. Biondi, Jr., Robert A. Bradway, François de Carbonnel, Vance D. Coffman, Robert A. Eckert, Greg C. Garland, Rebecca M. Henderson, Frank C. Herringer, Tyler Jacks, Judith...

2014-05-13 16:26:32

THOUSAND OAKS, Calif., May 13, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the publication of data from the Phase 3 LAPLACE-2 (LDL-C Assessment with PCSK9 MonoclonaL Antibody Inhibition Combined with Statin ThErapy-2) study in the Journal of the American Medical Association (JAMA). Results from the 12-week study, which evaluated 1,896 patients with high cholesterol, showed treatment with subcutaneous evolocumab (140 mg every two weeks or 420 mg monthly) in combination with...

2014-05-12 16:29:02

THOUSAND OAKS, Calif., May 12, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced the appointment of Steven K. Galson, M.D., M.P.H., to the position of senior vice president, Global Regulatory Affairs and Safety, effective May 19. Galson will report to Sean E. Harper, M.D., executive vice president, Research and Development, and will be responsible for all regulatory and patient safety functions across Amgen. Galson joined Amgen as vice president of Global Regulatory Affairs...

2014-05-12 16:27:12

Amgen Is Building World's Largest Cancer Support Team THOUSAND OAKS, Calif., May 12, 2014 /PRNewswire/ -- Amgen today announced that four individuals who are an inspiration for others affected by cancer have been selected as Breakaway from Cancer(®) Champions. They will be honored as part of Amgen's Breakaway from Cancer national initiative, designed to raise awareness of the important resources available to those impacted by cancer - from prevention to survivorship - during the ninth annual...

2014-05-12 08:31:40

SANTA MONICA, Calif., May 12, 2014 /PRNewswire/ -- Kite Pharma, Inc. (Kite), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT(TM)) products for the treatment of cancer, today announced the appointment of Jeffrey S. Wiezorek, M.D., M.S., to the newly created position of Vice President, Clinical Development. Dr. Wiezorek will assume responsibilities for leading Kite Pharma's clinical programs upon the retirement of Chief...

2014-05-09 16:24:31

Study Evaluating Novel Investigational IL-17 Receptor Antibody Meets All Primary and Secondary Endpoints THOUSAND OAKS, Calif. and LONDON, May 9, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and AstraZeneca today announced that the Phase 3 AMAGINE-1(TM) study evaluating brodalumab in patients with moderate-to-severe plaque psoriasis met all primary and secondary endpoints for both evaluated doses. Brodalumab is the only investigational treatment in development that binds to the...

2014-05-08 12:27:42

Cycling Fans Gain Unprecedented Access to All of the Action from the Peloton and Beyond via the Amgen Tour of California Social Hub Presented by Visit California LOS ANGELES, May 8, 2014 /PRNewswire/ -- Today, Amgen Tour of California, America's largest and most prestigious cycling event, and Visit California announced the launch of a new social platform, the "Amgen Tour of California Social Hub presented by Visit California." Photo -...

2014-05-07 04:22:16

OXFORD, England and SAN JOSE, May 7, 2014 /PRNewswire/ -- Oxford BioTherapeutics, an international biotechnology company focused on the development of innovative antibody-drug conjugates (ADCs) for the treatment of cancer, announced today that it has obtained the exclusive global rights to certain Xenomouse(R) antibodies generated by Amgen and to ImmunoGen's maytansinoid ADC technology for an undisclosed target. The rights were granted under the existing strategic...

2014-05-02 16:24:49

THOUSAND OAKS, Calif., May 2, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Deutsche Bank 39(th) Annual Healthcare Conference at 2:50 p.m. ET on Wednesday, May 7, 2014, at the InterContinental Hotel in Boston. Michael Severino, M.D., senior vice president of Global Development and corporate chief medical officer at Amgen, will present at the conference. Live audio of the presentation can be accessed from the Events Calendar on Amgen's website, www.amgen.com, under...


Word of the Day
abrosia
  • Wasting away as a result of abstinence from food.
The word 'abrosia' comes from a Greek roots meaning 'not' and 'eating'.